Guiding Immune Checkpoint Inhibitor Therapy
Emerging evidence indicates that one central common denominator of resistance to immune checkpoint inhibitors may be fibrotic activity characterized by collagen production by cancer-associated fibroblasts (CAFs).
Consequent to increased fibroblast activity, specific collagen fragments are released into the circulation and can be used as non-invasive biomarkers assessed in a liquid biopsy such as serum or plasma. PRO-C3 quantifies the formation of type III collagen and can therefore be used as a non-invasive biomarker of tumor fibrosis.
Watch more videos about Nordic Bioscience’s biomarkers and technology on our YouTube channel!